Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers

BACKGROUND: The programmed death-ligand 1 inhibitor atezolizumab had shown clinical activity against several advanced malignancies. PATIENTS AND METHODS: This phase II, open-label basket study (NCT02458638) was conducted in 16 main cohorts of patients aged ≥18 years with stage III or IV solid tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabernero, J., Andre, F., Blay, J.-Y., Bustillos, A., Fear, S., Ganta, S., Jaeger, D., Maio, M., Mileshkin, L., Melero, I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058880/
https://www.ncbi.nlm.nih.gov/pubmed/35305400
http://dx.doi.org/10.1016/j.esmoop.2022.100419

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058880/
https://www.ncbi.nlm.nih.gov/pubmed/35305400
http://dx.doi.org/10.1016/j.esmoop.2022.100419

Ejemplares similares